CompletedPhase 2NCT06235775

Administration of GV1001 for the Treatment of Progressive Supranuclear Palsy Who Completed Study GV1001-PSP-CL2-011

Studying Classic progressive supranuclear palsy syndrome

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
GemVax & Kael
Principal Investigator
Sang Jae Kim
GemVax & Kael
Intervention
GV1001 Placebo(drug)
Enrollment
67 enrolled
Eligibility
41-85 years · All sexes
Timeline
20232025

Study locations (5)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT06235775 on ClinicalTrials.gov

Other trials for Classic progressive supranuclear palsy syndrome

Additional recruiting or active studies for the same condition.

See all trials for Classic progressive supranuclear palsy syndrome

← Back to all trials